Teva Pharmaceutical Industries Ltd. ADR (TEVA): Price and Financial Metrics


Teva Pharmaceutical Industries Ltd. ADR (TEVA): $8.83

0.60 (+7.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TEVA POWR Grades

  • Growth is the dimension where TEVA ranks best; there it ranks ahead of 98.33% of US stocks.
  • TEVA's strongest trending metric is Stability; it's been moving down over the last 177 days.
  • TEVA ranks lowest in Momentum; there it ranks in the 17th percentile.

TEVA Stock Summary

  • TEVA's went public 32.53 years ago, making it older than 85.55% of listed US stocks we're tracking.
  • Revenue growth over the past 12 months for TEVA PHARMACEUTICAL INDUSTRIES LTD comes in at -5.45%, a number that bests only 16.57% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TEVA comes in at 23.08% -- higher than that of 91.86% of stocks in our set.
  • Stocks that are quantitatively similar to TEVA, based on their financial statements, market capitalization, and price volatility, are AGFS, AYTU, FLNT, ELAN, and LNDC.
  • TEVA's SEC filings can be seen here. And to visit TEVA PHARMACEUTICAL INDUSTRIES LTD's official web site, go to www.tevapharm.com.

TEVA Valuation Summary

  • TEVA's price/earnings ratio is -8.3; this is 142.35% lower than that of the median Healthcare stock.
  • TEVA's price/sales ratio has moved down 3.4 over the prior 240 months.

Below are key valuation metrics over time for TEVA.

Stock Date P/S P/B P/E EV/EBIT
TEVA 2022-09-23 0.6 1.0 -8.3 -31.1
TEVA 2022-09-22 0.6 1.0 -8.5 -31.3
TEVA 2022-09-21 0.6 1.0 -8.7 -31.5
TEVA 2022-09-20 0.6 1.0 -8.9 -31.7
TEVA 2022-09-19 0.6 1.1 -9.1 -32.0
TEVA 2022-09-16 0.6 1.1 -9.3 -32.2

TEVA Growth Metrics

    Its year over year price growth rate is now at -15.02%.
  • Its 4 year price growth rate is now at -68.59%.
  • The 3 year cash and equivalents growth rate now stands at 10.24%.
TEVA's revenue has moved down $6,469,000,000 over the prior 67 months.

The table below shows TEVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 15,434 1,059 -1,054
2022-03-31 15,558 1,154 -615
2021-12-31 15,878 798 417
2021-09-30 16,232 673 726
2021-06-30 16,323 451 -3,915
2021-03-31 16,283 506 -3,982

TEVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TEVA has a Quality Grade of C, ranking ahead of 57.93% of graded US stocks.
  • TEVA's asset turnover comes in at 0.33 -- ranking 140th of 682 Pharmaceutical Products stocks.
  • LFVN, ONVO, and ANAB are the stocks whose asset turnover ratios are most correlated with TEVA.

The table below shows TEVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.330 0.468 0.064
2021-06-30 0.329 0.469 -0.088
2021-03-31 0.319 0.463 -0.097
2020-12-31 0.316 0.464 -0.102
2020-09-30 0.298 0.471 -0.108
2020-06-30 0.293 0.462 0.018

TEVA Stock Price Chart Interactive Chart >

Price chart for TEVA

TEVA Price/Volume Stats

Current price $8.83 52-week high $11.34
Prev. close $8.23 52-week low $6.78
Day low $8.38 Volume 12,268,345
Day high $8.83 Avg. volume 10,720,357
50-day MA $9.34 Dividend yield N/A
200-day MA $8.62 Market Cap 9.81B

Teva Pharmaceutical Industries Ltd. ADR (TEVA) Company Bio


Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces, and markets, generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines. Established in 1901, the company markets 3,500 generic and proprietary products to 60 countries worldwide. Teva competes against other large pharmaceutical companies such as Pfizer, Merck, Novartis, and GlaxoSmithKline. Kare Schulz currently serves as Teva’s President, Chairman of the Board, and Chief Executive Officer, overseeing an international workforce of around 38,000 employees.


TEVA Latest News Stream


Event/Time News Detail
Loading, please wait...

TEVA Latest Social Stream


Loading social stream, please wait...

View Full TEVA Social Stream

Latest TEVA News From Around the Web

Below are the latest news stories about TEVA PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TEVA as an investment opportunity.

Why Teva Stock Shot More Than 3% Higher Today

Teva Pharmaceutical Industries (NYSE: TEVA) stock closed the trading week in style, rising by over 3% on a bleak and bearish day for the wider market. Teva Pharmaceuticals, the company's key subsidiary, has reached an agreement with the southern state's attorney general to settle accusations of price-fixing. Under the terms of the arrangement, Teva is to pay just under $3.35 million; in return, once the funds are handed over Georgia will dismiss all claims against the company in the case.

Yahoo | September 30, 2022

Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims

TEL AVIV, Israel & PARSIPPANY, N.J., September 30, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached an agreement with the Attorney General (AG) of Georgia to settle the state’s price-fixing claims against Teva. Teva will pay the state $3.346 million as part of the settlement, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made.

Yahoo | September 30, 2022

European Drug Makers Say Higher Energy Costs Eating Margins: Report

Europe's drug makers have warned about stopping manufacturing some cheap generic medicines amid surging electricity costs. The generic drug industry lobby group, Medicines for Europe, representing Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Novartis AG's (NYSE: NVS) Sandoz unit, and Fresenius SE's (OTC: FSNUY) Kabi business, sent a letter to European states' energy and health ministers, asking for measures to relieve the cost burden. According to Medicines for Europe, Generic associations p

Yahoo | September 27, 2022

Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD Chorea

TEL AVIV, Israel & PARSIPPANY, N.J., September 26, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of the Honestly HD website, which aims to provide information, inspiration and resources to help people understand what to expect with Huntington’s Disease (HD) chorea – one of the most visible and treatable symptoms of HD – and, how to talk to their doctor about preserving independence. In addition to the newly l

Yahoo | September 26, 2022

Op-Ed: Prevent a legal catch-22 that could push thousands of generic drugs off the market

To avert a collision of patents and safety regulations, the Supreme Court must ensure that a damaging ruling is quickly undone.

Yahoo | September 21, 2022

Read More 'TEVA' Stories Here

TEVA Price Returns

1-mo -0.11%
3-mo 16.95%
6-mo -13.26%
1-year -8.21%
3-year 26.69%
5-year -43.39%
YTD 10.24%
2021 -16.99%
2020 -1.53%
2019 -36.45%
2018 -18.63%
2017 -46.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6388 seconds.